Therapy Areas: Central Nervous System
Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA
8 July 2022 - - France-based phase 3 gene therapy platform company Lysogene (PAR: LYS) (FR0013233475 LYS) is presenting additional preliminary data from the AAVance Phase 2/3 gene therapy trial in MPS IIIA (NCT03612869), the company said.

Data will be presented at the ADVANCE 2022 Sanfilippo Community Conference held on July 7-8, 2022, and at the 3rd Annual Gene Therapy for Neurological Disorders Europe held on July 11-13, 2022.

According to the company, a positive effect of LYS-SAF302 on the MPS IIIA disease biomarker heparan sulfate in the cerebrospinal fluid was confirmed in additional subjects and at additional timepoints relative to previously communicated partial data.

Statistically significant decreases of about 20% in average levels of total HS-derived oligosaccharides in the CSF relative to baseline levels were observed at 6, 12 and 24 months after dosing with LYS-SAF302.

HS levels at 24 months after dosing with LYS-SAF302 (1654 ± 497 ng/ml, mean ± SD, n=15) were decreased by 22% relative to baseline levels (2159 ± 589 ng/ml, mean ± SD, n=16), p=0.015 by Student's t test (preliminary analysis). No statistically significant effect on serum HS levels was observed at 6, 12 or 24 months after dosing with LYS-SAF302.

These results confirm the biological activity of LYS-SAF302 gene therapy treatment. They are consistent with the intraparenchymal mode of administration of LYS-SAF302, which is expected to lead to a specific decrease of HS in the brain, but not in the systemic circulation nor in other tissues, including the spinal cord.

The previous observation that treatment with LYS-SAF302 led to a transient increase in serum neurofilament light levels, likely due to transient axonal damage caused by brain surgery, followed by a decrease below baseline levels, was confirmed in additional subjects and at additional timepoints. Moreover, a similar effect was demonstrated in the CSF.

In the serum, NFL levels decreased by 33% (n=12, p=0.026) and 41% (n=16, p=0.0075) below baseline levels (113 ± 50 pg/ml, mean ± SD, n=19), 18 and 24 months after dosing with LYS-SAF302, respectively.

In the CSF, NFL levels decreased by 33% (n=15, p=0.025) below baseline levels (3.7 ± 1.5 ng/ml, mean ± SD, n=17) 24 months after dosing with LYS-SAF302.

All statistical analyses were done by Student's t test and are preliminary. These results suggest that treatment with LYS-SAF302 led to a decrease in neuronal damage relative to baseline at 18 and 24 months after drug administration.

Three subjects in AAVance, treated at 10, 13 and 31 months of age, present continuous increase of cognitive, language and motor functions 24 months after dosing with LYS-SAF302, as assessed by the BSID-III (Bayley's Scales of Infant Development, Third edition).

Two of these subjects have a cognitive developmental age at 24 months after dosing with LYS-SAF302 that is 5-6 months higher (41 and 42, respectively) than the highest cognitive DA observed in natural history studies of MPS IIIA (Shapiro et al, 2016; Wijburg et al 2022).

Remarkably, one of these subjects is homozygous for a severe mutation (deletion) and the other subject is compound heterozygous for two severe mutations (a duplication and a deletion).

The third subject with continuously increasing DA at 24 months after dosing with LYS-SAF302 is a compound heterozygote for a severe mutation and a S298P mutation, which may give rise to either a classical severe or an intermediate phenotype.

Longer follow-up is warranted to confirm positive evolution of development in this patient.

Three other subjects, treated at 24, 30 and 31 months of age, have stable cognitive DA relative to baseline, as assessed by the BSID-III scale, and stable or continuously increasing BSID-III language and motor development scores at 24 months after dosing with LYS-SAF302.

Two of these subjects have SGSH missense mutations associated with the classical severe phenotype of MPS IIIA. One subject has a severe mutation on one allele and a mutation with unknown effect on disease severity on the second allele.

The fact that developmental progression or stabilization is seen in subjects with mutations associated with the classical severe disease phenotype suggests that early therapeutic intervention with LYS-SAF302 can protect children with MPS IIIA from decline of cognitive, language, and motor functions, the company said.

The AAVance trial Month 24 database lock took place as planned on 1st of July 2022. Full study results are expected by mid-September 2022, along with results from the PROVide patient reported outcome videos study.

Based on this comprehensive clinical data package, the company plans to initiate discussions with regulatory authorities in the US and in Europe to determine next steps.

Lysogene is a gene therapy company focused on the treatment of orphan diseases of the central nervous system.
Login
Username:

Password:


Related Headlines